Summary of "How Many Mg Of Retatrutide Should I Take"

Key wellness strategies & takeaways (from the subtitles)

Retatrutide is described as a triple-agonist, sometimes referenced as:
- “GLP-1 / GIP / glucagon” stacked together
- Occasionally (and confusingly) compared to “GLP-3”
Claimed mechanism focus:
- Improves insulin sensitivity / glucose handling (via GIP)
- Supports metabolic signaling, while aiming to avoid excess blood-sugar problems (via the GLP-1 + glucagon combination)
It’s presented as potentially affecting more than weight, including longevity-related markers.

The speaker references a New England Journal of Medicine study titled:

Dosing groups discussed:

Weight-loss results (percent body weight loss over 48 weeks, as stated):

Wellness/productivity framing:

If the goal is purely weight loss, the speaker points toward higher-dose ranges (including the ~12 mg/week reference).
If the goal is longevity / healthspan, the speaker prefers lower starting doses with slower titration.

Claimed benefits emphasized:

Observational/secondary claims mentioned about GLP-1s:

Lower risk of heart disease
Lower risk of cancer
Lower risk of dementia / Alzheimer’s
Example cited: ~12% lower rate of Alzheimer’s (noted as potentially not statistically significant)

Start: ~0.5 mg/week
Titrate upward gradually:
- stay at 0.5 mg/week for 3–4 weeks
- then increase to 1 mg
Typical range suggested: 1–2 mg/week
“Therapeutic pulse” concept:
- aim for enough receptor activation, rather than frequent micro-dosing

The speaker cites literature reaching as high as ~12 mg/week (described as “enormous”).
Cautions against micro-dosing:
- doing it 3 times per week “isn’t going to work the same way” (as claimed by the speaker)
- rationale given: need sufficient concentration to activate receptors

Retatrutide is described as having a ~144-hour half-life (≈ 6 days), so re-dosing is framed around a weekly schedule.

Peptide sourcing purity warning:
- avoid “research use only” sources that may be problematic (as claimed)
Recommendation for compounding facilities:
- use licensed compounding facilities: 503A / 503B (as stated)

The speaker suggests other peptides to stack with retatrutide, depending on goals:

Strong emphasis on individualization:
- get blood labs
- build a personalized peptide stack
- reassess monthly with ongoing optimization

Presenter: Reagan Archbald (founder of Ageless Future)
Source referenced: New England Journal of Medicine (NEJM) study (2023)
- “Triple hormone receptor agonist retatrutide in adults with obesity”